Prolira is committed to enabling early and effective treatment of acute encephalopathy and delirium. Every year, 20 million patients are at risk of acute brain failure in EU and US hospitals, which leads to long-term cognitive impairment, extended hospital stays, and increased healthcare costs.

Prolira’s DeltaScan® Brain State Monitor is the